Overview

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

Status:
Withdrawn

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

This is a randomized, multi-center, open-label study of approximately 24 months duration (including follow up survival) to evaluate the safety and efficacy of obatoclax mesylate in combination with carboplatin and etoposide versus carboplatin and etoposide alone in chemotherapy-naive patients with extensive-stage small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Cephalon

Treatments:

Carboplatin
Etoposide
Etoposide phosphate
Obatoclax